Palatin Technologies (LSE:0KF3) - Hisse Senedi Fiyatı, Haberler ve Analizler

0KF3 Stoklara Genel Bakış

0KF3 temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	1/6
Temettüler	0/6

Risk Analizi

Kazançlar son 5 yılda yılda 31.4% oranında azaldı

1 yıldan az nakit akışı var

Negatif hissedar öz sermayesi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

+ 3 daha fazla risk

Palatin Technologies, Inc. Rakipler

Arecor Therapeutics

AIM:AREC

UK£28.3m

ProBiotix Health

OFEX:PBX

UK£10.7m

Tissue Regenix Group

AIM:TRX

UK£40.6m

Verici Dx

AIM:VRCI

UK£8.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Palatin Technologies
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.13
52 Haftanın En Yüksek Seviyesi	US$5.45
52 Haftanın En Düşük Seviyesi	US$0.70
Beta	0.94
11 Aylık Değişim	0.71%
3 Aylık Değişim	-31.41%
1 Yıllık Değişim	-40.03%
33 Yıllık Değişim	-93.00%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-95.07%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	0KF3	GB Biotechs	GB Pazar
7D	12.8%	1.5%	2.2%
1Y	-40.0%	-17.9%	8.8%

Getiri vs. Endüstri: 0KF3 geçen yıl % -17.9 oranında getiri sağlayan UK Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: 0KF3 geçen yıl % 8.8 oranında getiri sağlayan UK Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 0KF3's price volatile compared to industry and market?
0KF3 volatility
0KF3 Average Weekly Movement	20.1%
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: 0KF3 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 0KF3 'nin haftalık oynaklığı ( 20% ) geçen yıl boyunca sabit kaldı, ancak hala UK hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1986	30	Carl Spana	palatin.com

Bir biyofarmasötik şirketi olan Palatin Technologies, Inc. Amerika Birleşik Devletleri'nde çeşitli hastalıkların tedavisi için hedefe yönelik reseptöre özgü terapötikler geliştirmektedir. Şirketin öncü ürünü, hipoaktif cinsel istek bozukluğu olan premenopozal kadınların tedavisi için bir melanokortin reseptörü (MCr) agonisti olan Vyleesi'dir. Ayrıca, inflamatuar bağırsak hastalıklarının tedavisi için Faz 2 klinik çalışmasında olan seçici bir MC1r agonist peptidi olan oral PL8177'yi geliştirmektedir.

Palatin Technologies, Inc. Temel Bilgiler Özeti

Palatin Technologies'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
0KF3 temel i̇stati̇sti̇kler
Piyasa değeri	US$21.50m
Kazançlar(TTM)	-US$32.35m
Gelir(TTM)	US$2.38m

9.0x

P/S Oranı

-0.7x

F/K Oranı

0KF3 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
0KF3 gelir tablosu (TTM)
Gelir	US$2.38m
Gelir Maliyeti	US$23.23m
Brüt Kâr	-US$20.84m
Diğer Giderler	US$11.51m
Kazançlar	-US$32.35m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.66
Brüt Marj	-874.25%
Net Kâr Marjı	-1,357.06%
Borç/Özkaynak Oranı	0%

0KF3 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

0KF3 Stoklara Genel Bakış

Risk Analizi

Palatin Technologies, Inc. Rakipler

AIM:AREC

UK£28.3m

OFEX:PBX

UK£10.7m

AIM:TRX

UK£40.6m

AIM:VRCI

UK£8.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Palatin Technologies, Inc. Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

First quarter 2025 earnings released: US$0.39 loss per share (vs US$0.48 loss in 1Q 2024)

Palatin Technologies, Inc. to Report Q1, 2025 Results on Nov 14, 2024

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule Pl7737 Obesity Program at Obesityweek 2024

Palatin Technologies, Inc. Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Palatin Technologies, Inc. Presents Illustrates Data from Clinical and Preclinical Studies for Three Proprietary Melanocortin Agonists

Recent updates

Palatin Technologies, Inc. Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

First quarter 2025 earnings released: US$0.39 loss per share (vs US$0.48 loss in 1Q 2024)

Palatin Technologies, Inc. to Report Q1, 2025 Results on Nov 14, 2024

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule Pl7737 Obesity Program at Obesityweek 2024

Palatin Technologies, Inc. Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Palatin Technologies, Inc. Presents Illustrates Data from Clinical and Preclinical Studies for Three Proprietary Melanocortin Agonists

Palatin Receives Notice of Non-Compliance from NYSE American

New major risk - Revenue and earnings growth

Full year 2024 earnings released: US$2.02 loss per share (vs US$2.21 loss in FY 2023)

Palatin Technologies, Inc. to Report Q4, 2024 Results on Oct 01, 2024

Palatin Technologies, Inc., Annual General Meeting, Dec 12, 2024

Palatin Technologies, Inc. Announces FDA Confirms Acceptability of Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

Palatin Technologies, Inc. Announces First Patient Dosed in Phase 2 Clinical Study of Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

New major risk - Shareholder dilution

Forecast to breakeven in 2027

Palatin Technologies, Inc. Announces Initiation of Phase 2 Clinical Study of Bremelanotide Co-Administered with PDE5i for Treatment of Erectile Dysfunction

Palatin Technologies, Inc. Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

Palatin Technologies, Inc., Annual General Meeting, Jun 27, 2024

Third quarter 2024 earnings released: US$0.53 loss per share (vs US$0.63 loss in 3Q 2023)

Palatin Technologies, Inc. to Report Q3, 2024 Results on May 15, 2024

Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease (Ded) Clinical Data Results Presented At American Society of Cataract and Refractive Surgery (Ascrs) 2024

No longer forecast to breakeven

New minor risk - Profitability

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.13 loss in 2Q 2023)

Palatin Announces Database Lock for PL9643 Melody-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Palatin Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $10.000006 million.

Palatin Technologies, Inc. Provides Corporate Update and Highlights Strategic Priorities for Year 2024

Forecast to breakeven in 2026

Palatin Technologies Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

First quarter 2024 earnings released: US$0.48 loss per share (vs US$0.86 loss in 1Q 2023)

New major risk - Negative shareholders equity

Palatin Technologies, Inc. to Report Q1, 2024 Results on Nov 14, 2023

Palatin Technologies, Inc. announced that it expects to receive $5.000001 million in funding

Palatin Technoloes, Inc. Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients

Palatin Receives Notice of Non-Compliance from NYSE American

Palatin Receives Notice of Non-Compliance from NYSE American

Full year 2023 earnings released: US$2.53 loss per share (vs US$3.79 loss in FY 2022)

Palatin Technologies, Inc. to Report Q4, 2023 Results on Sep 28, 2023

Insufficient new directors

Palatin Technologies, Inc. Completes Enrollment in Phase 3 Melody-1 Study of PL9643 for the Treatment of Patients with Dry Eye Disease

Palatin Technologies, Inc. Initiates Clinical Program for Bremelanotide Co-Formulated with A Pde5i for the Treatment of Ed in Patients Non-Responsive to Pde5i Treatment

Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

Palatin Technologies, Inc., Annual General Meeting, Jun 20, 2023

Third quarter 2023 earnings released: US$0.63 loss per share (vs US$0.80 loss in 3Q 2022)

Palatin Technologies, Inc. to Report Q3, 2023 Results on May 16, 2023

Palatin Technologies, Inc. Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference

Insufficient new directors

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.91 loss in 2Q 2022)

Palatin Technologies, Inc. to Report Q2, 2023 Results on Feb 15, 2023

Insufficient new directors

Palatin Technologies Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions

Forecast to breakeven in 2025

Insufficient new directors

Palatin Technologies, Inc. to Report Q1, 2023 Results on Nov 14, 2022

Palatin Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $9.999921 million.

Palatin Technologies, Inc. Announces First Patient Has Been Enrolled in the Pl8177-205 Study with Palatin's Pl8177

Insufficient new directors

Full year 2022 earnings released: US$3.79 loss per share (vs US$3.55 loss in FY 2021)

Palatin Technologies, Inc. to Report Q4, 2022 Results on Sep 22, 2022